<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206452</url>
  </required_header>
  <id_info>
    <org_study_id>12153</org_study_id>
    <nct_id>NCT01206452</nct_id>
  </id_info>
  <brief_title>Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes</brief_title>
  <official_title>Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dhanunjaya Lakkireddy, MD, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the efficacy of oral prednisone in improving
      the outcomes of pulmonary vein isolation with radiofrequency ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is:

        1. To assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein
           isolation with radiofrequency ablation.

        2. To measure the inflammatory cytokine (TNF-α, IL-1, IL-6, IL-8) response to
           radiofrequency ablation for atrial fibrillation with or without prior prednisone
           treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Atrial Fibrillation Recurrence From 6 Months up to 12 Months</measure>
    <time_frame>From 6 months up to 12 months post-procedure</time_frame>
    <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 6 and 12 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Atrial Fibrillation Recurrence From 0 Months up to 3 Months</measure>
    <time_frame>From 0 months up to 3 months post procedure</time_frame>
    <description>Number of AF recurrences between the two study groups as assessed by inpatient telemetry in the immediate post-procedure period until discharge and 1-month event monitor placed at 3 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Atrial Fibrillation Recurrence From 3 Months up to 6 Months</measure>
    <time_frame>From 3 months up to 6 months post-procedure</time_frame>
    <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 3 and 6 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Cytokine Response to Ablation Procedure</measure>
    <time_frame>Immediately Post-Ablation Procedure</time_frame>
    <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, immediately post-ablation in keeping with prior studies on the anti-inflammatory effects of steroids following cardiac surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Cytokine Response to Ablation Procedure</measure>
    <time_frame>24 Hours after Ablation Procedure</time_frame>
    <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, 24 hours post-ablation to assess interval response to steroid administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Ablation plus prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ablation plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants undergo ablation procedure and receive placebo at protocol determined times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure</description>
    <arm_group_label>Ablation plus prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure</description>
    <arm_group_label>Ablation plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation Procedure</intervention_name>
    <description>Atrial Fibrillation (AF) ablation</description>
    <arm_group_label>Ablation plus prednisone</arm_group_label>
    <arm_group_label>Ablation plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent;

          2. Scheduled for radiofrequency ablation procedure for treatment of atrial fibrillation

        Exclusion Criteria:

          1. History of heart failure (right or left or biventricular) or cardiomyopathy.

          2. Immunosuppressive disorders and systemic fungal infection

          3. Concurrent use of corticosteroids in one week prior recruitment.

          4. Allergy or prednisone or its components.

          5. Other medical conditions were use of corticosteroids is not recommended or
             contraindicated.

          6. Patients with chronic and permanent atrial fibrillation.

          7. Patients with established diagnosis of rheumatological and immunological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>January 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Dhanunjaya Lakkireddy, MD, FACC</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation; Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ablation Plus Placebo</title>
          <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
        <group group_id="P2">
          <title>Ablation Plus Prednisone</title>
          <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ablation Plus Placebo</title>
          <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
        <group group_id="B2">
          <title>Ablation Plus Prednisone</title>
          <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.23" spread="8.95"/>
                    <measurement group_id="B2" value="63" spread="8.69"/>
                    <measurement group_id="B3" value="63.12" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.48" spread="5.19"/>
                    <measurement group_id="B2" value="30.53" spread="5.93"/>
                    <measurement group_id="B3" value="29.51" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AF Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.92" spread="7.66"/>
                    <measurement group_id="B2" value="4.98" spread="4.81"/>
                    <measurement group_id="B3" value="6.45" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Atrial Fibrillation Recurrence From 6 Months up to 12 Months</title>
        <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 6 and 12 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
        <time_frame>From 6 months up to 12 months post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ablation Plus Placebo</title>
            <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
          <group group_id="O2">
            <title>Ablation Plus Prednisone</title>
            <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Atrial Fibrillation Recurrence From 6 Months up to 12 Months</title>
          <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 6 and 12 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
          <units>Participants with AF recurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Atrial Fibrillation Recurrence From 0 Months up to 3 Months</title>
        <description>Number of AF recurrences between the two study groups as assessed by inpatient telemetry in the immediate post-procedure period until discharge and 1-month event monitor placed at 3 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
        <time_frame>From 0 months up to 3 months post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ablation Plus Placebo</title>
            <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
          <group group_id="O2">
            <title>Ablation Plus Prednisone</title>
            <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Atrial Fibrillation Recurrence From 0 Months up to 3 Months</title>
          <description>Number of AF recurrences between the two study groups as assessed by inpatient telemetry in the immediate post-procedure period until discharge and 1-month event monitor placed at 3 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
          <units>Participants with AF recurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Atrial Fibrillation Recurrence From 3 Months up to 6 Months</title>
        <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 3 and 6 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
        <time_frame>From 3 months up to 6 months post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ablation Plus Placebo</title>
            <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
          <group group_id="O2">
            <title>Ablation Plus Prednisone</title>
            <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Atrial Fibrillation Recurrence From 3 Months up to 6 Months</title>
          <description>Number of AF recurrences between the two study groups as assessed by 1-month event monitor placed at 3 and 6 months post-ablation. Any episode of AF lasting greater than 30 seconds was counted as a recurrence.</description>
          <units>Participants with AF recurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Cytokine Response to Ablation Procedure</title>
        <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, immediately post-ablation in keeping with prior studies on the anti-inflammatory effects of steroids following cardiac surgery.</description>
        <time_frame>Immediately Post-Ablation Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ablation Plus Placebo</title>
            <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
          <group group_id="O2">
            <title>Ablation Plus Prednisone</title>
            <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Cytokine Response to Ablation Procedure</title>
          <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, immediately post-ablation in keeping with prior studies on the anti-inflammatory effects of steroids following cardiac surgery.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.8"/>
                    <measurement group_id="O2" value="7.94" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="8.14"/>
                    <measurement group_id="O2" value="10.54" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="3.2"/>
                    <measurement group_id="O2" value="5.45" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.78" spread="13.19"/>
                    <measurement group_id="O2" value="9.03" spread="7.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Cytokine Response to Ablation Procedure</title>
        <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, 24 hours post-ablation to assess interval response to steroid administration.</description>
        <time_frame>24 Hours after Ablation Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ablation Plus Placebo</title>
            <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
          <group group_id="O2">
            <title>Ablation Plus Prednisone</title>
            <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Cytokine Response to Ablation Procedure</title>
          <description>Measure inflammatory marker levels, including IL-1, IL-6, IL-8, and TNF-α, 24 hours post-ablation to assess interval response to steroid administration.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="15.4"/>
                    <measurement group_id="O2" value="8.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="54.9"/>
                    <measurement group_id="O2" value="63.9" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="15.8"/>
                    <measurement group_id="O2" value="7.5" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="39.9"/>
                    <measurement group_id="O2" value="40.2" spread="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ablation Plus Placebo</title>
          <description>Participants undergo ablation procedure and receive placebo at protocol determined times.
Placebo: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
        <group group_id="E2">
          <title>Ablation Plus Prednisone</title>
          <description>Participants undergo ablation procedure and receive predinisone at protocol determined times.
Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Ablation Procedure: Atrial Fibrillation (AF) ablation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Groin hematoma</sub_title>
                <description>Related to ablation procedure. No subjects required blood transfusions or surgical repair.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donita Atkins, RN, CCRC</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-9714</phone>
      <email>datkins2@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

